Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes

Immunology

Volumn 107, Issue 4, 2002, Pages 472-479

  Kim, Kwang Mi ^a   Won Kim, Ho ^a   Kim, Jae Ouk ^a   Baek, Kyoung Min ^a   Gon Kim, Joong ^a   Kang, Chang Yuil ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CD137 ANTIGEN; CD3 ANTIGEN; DOXORUBICIN; MITOMYCIN C; TUMOR NECROSIS FACTOR; ANTINEOPLASTIC AGENT; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA; MITOMYCIN; NERVE GROWTH FACTOR RECEPTOR; TNFRSF9 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG EXPOSURE; GAMMA IRRADIATION; GENOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; MONOCYTE; MONONUCLEAR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; RADIATION DOSE; T LYMPHOCYTE; CELL CULTURE; CELL DIVISION; DRUG EFFECT; FLOW CYTOMETRY; GAMMA RADIATION; GENE EXPRESSION; GENETICS; IMMUNOLOGY; METHODOLOGY; RADIATION EXPOSURE;

ANTIGENS, CD; ANTIGENS, CD137; ANTINEOPLASTIC AGENTS; BLEOMYCIN; CELL DIVISION; CELLS, CULTURED; DNA DAMAGE; DOXORUBICIN; FLOW CYTOMETRY; GAMMA RAYS; GENE EXPRESSION; HUMANS; MITOMYCIN; MONOCYTES; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 0036884764     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2002.01538.x     Document Type: Article

References (55)

1. Kwon BS, Weissman SM. cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci USA 1989; 86:1963-7.
2. Mallett S, Barclay AN. A new superfamily of cell surface proteins related to the nerve growth factor receptor. Immunol Today 1991; 12:220-2.
3. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins. Activation, Costimulation, Death Cell 1994; 76:959-62.
4. Armitage RJ. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Iinmunol 1994; 6:407-13.
5. Pollok KE, Kim YH, Zhou Z, Hurtado J, Kim KK, Pickard RT, Kwon BS. Inducible T-cell antigen 4-1BB. An analysis of expression and function. J Immunol 1993; 150:771-81.
6. + T cell proliferation and lead to the amplification of in vivo cytotoxic T cell responses. J Exp Med 1997; 186:47-55.
7. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CD137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998; 190:167-72.
8. Futagawa T, Akiba H, Kodama T, Takeda K, Hosoda Y, Yagita H, Okumura K. Expression and function of 4-1BB and 4-1BBL on murine dendritic cells. Int Immunol 2002; 14:275-86.
9. Kienzle G, von Kempis J. CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes. Int Immunol 2000; 12:73-82.
10. Broll K, Richter G, Pauly S, Hofstaedter F, Schwarz H. CD137 expression in tumor vessel walls. High correlation with malignant tumors. Am J Clin Pathol 2001; 115:543-9.
11. Pollok KE, Kim SH, Kwon BS. Regulation of 4-1BB expression by cell-cell interactions and cytokines, interlukin-2 and interlukin-4. Eur J Immunol 1995; 25:488-94.
12. Kwon BS, Kestler DP, Eshhar Z, Oh KO, Wakulchik M. Expression characteristics of two potential T cell mediator genes. Cell Immunol 1989; 121:414-22.
13. Kwon BS, Kim GS, Prystowsky MB, Lancki DW, Sabath DE, Pan JL, Weissman SM. Isolation and initial characterization of multiple species of T-lymphocyte subset cDNA clones. Proc Natl Acad Sci USA 1987; 84:2896-900.
14. Goodwin RG, Din WS, Davis-Smith T et al. Molecular cloning of a ligand for the inducible T-cell gene 4-1BB, a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol 1993; 23:2631-41.
15. Alderson MR, Smith CA, Tough TW et al. Molecular and biological characterization of human 4-1BB and its ligand. Eur J Immunol 1994; 24:2219-27.
16. DeBenedette MA, Chu NR, Pollok KE, Hurtado J, Wade WF, Kwon BS, Watts TH. Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphoma by cAMP. J Exp Med 1995; 181:985-92.
17. Pollok KE, Kim YJ, Hurtado J, Zhou Z, Kim KK, Kwon BS. 4-1BB T-cell antigen binds to mature B-cells and macrophages and costimulates anti-μ-primed splenic B cells. Eur J Immunol 1994; 24:367-74.
18. Schwarz H, Valbracht J, Tuckwell J, Von Kempis J, Lotz M. ILA, The human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood 1995; 85:1043-52.
19. - T lymphocytes by 4-1BB ligand. J Immunol 1997; 158:551-9.
20. Schwarz H, Blanco FJ, Von Kempis J, Valbracht J, Lotz M. ILA, a member of the human nerve growth factor/ tumor necrosis factor receptor family, regulates T-lymphocyte proliferation and survival. Blood 1996; 87:2839-45.
21. Hurtado JC, Kim SH, Pollok KE, Lee ZH, Kwon BS. Potential role of 4-1BB in T cell activation: comparison with the costimulatory molecule CD28. J Immunol 1995; 155:3360-7.
22. Saoulli K, Lee SY, Cannons JL et al. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J Exp Med 1998; 187:1849-62.
23. Hurtado JC, Kim YJ, Kwon BS. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol 1997; 158:2600-9.
24. Takahashi C, Mittler RS, Vella AT. 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999; 162:5037-40.
25. + T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melophalan therapy. Cancer Res 1990; 50:7641-9.
26. + T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor. Cancer Res 1989; 49:4597-606.
27. Yuan L, Kuramitsu Y, Li Y, Kobayashi M, Hosokawa M. Restoration of interleukin-2 production in tumor-bearing rats through reduction of tumor-derived transforming growth factor β by treatment with bleomycin. Cancer Immunol Immunother 1995; 41:355-62.
28. Nagarkatti M, Toney DM, Nagarkatti PS. Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngenic tumor. Cancer Res 1989; 49:6587-92.
29. + T-cells to cause recession of an advanced lymphoma. Immunology 1990; 71:90-5.
30. Sahasrabudhe DM, deKernion JB, Pontes JE, Ryan DM, O'donnell RW, Marquis DM, Mudholkar GS, McCune CS. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Response Modif 1986; 5:581-94.
31. Berd D, Mastrangelo MJ. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest 1988; 6:337-49.
32. Bass K, Mastrangelo MJ. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 1998; 47:1-12.
33. Sojka DK, Donepudi M, Bluestone JA, Mokyr MB. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J Immunol 2000; 164:6230-6.
34. Weiskirch LM, Bar-Dagan Y, Mokyr MB. Transforming growth factor-β-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor bearing mice engaged in tumor eradication following low-dose melphalan-therapy. Cancer Immunol Immunother 1994; 38:215-24.
35. Gorelik L, Prokhorova A, Mokyr MB. Low-dose melphalan-induced shift in the productin of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother 1994; 39:117-26.
36. Lattime EC, Mastrangelo MJ, Bagasra O, Li W, Berd D. Expression of cytokine mRNA in human melanoma tissue. Cancer Immunol Immunother 1995; 41:151-6.
37. Gorelik L, Rubin M, Prokhorova A, Mokyr MB. Importance of TNF production for the curative effectiveness of low-dose melphalan therapy for mice bearing a large MOPC-315 tumor. J Immunol 1995; 154:3941-51.
38. Gorelik L, Mokyr MB. Low-dose melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon-γ in the therapeutic outcome. Cancer Immunol Immunother 1995; 41:363-74.
39. Mokyr MB, Kalinichenko TV, Gorelik L. Potentiation of antitumor CTL response by GM-CSF involves a B7-dependent mechanism. Cell Immunol 1997; 178:152-61.
40. Matar P, Rozados VR, Ginzalez AD, Dlugovitzky DG, Bonfil RD, Scharovsky OG. Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide. Eur J Cancer 2000; 36:1060-6.
41. Vladimir MJ, Mokyr MB. Melphalan-induced expression of IFN-β in MOPC-315 tumor-bearing mice and its importance for the upregulation of TNF-β expression. J Immunol 2001; 167:4895-901.
42. Lee SH, Lee NG, Suh SY, Kim JG, Choi EC, Kang CY. Characterization of immunological and molecular properties of an anti-human 4-1BB monoclonal antibody. Mol Cells 1996; 6:161-8.
43. Kang CY, Hariharan K, Nara PL, Sodroski J, Moore JP. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. J Virol 1994; 68:5854-62.
44. Muller C, Chatelut E, Gualano V, De Forni M, Huguet F, Attal M, Canal P, Laurent G. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother Pharmacol 1993; 32:379-84.
45. Hall SW, Strong JE, Broughton A, Frazier ML, Benjamin RS. Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol 1982; 9:22-5.
46. Muller M, Wilder S, Bannasch D et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998; 188:2033-45.
47. Glisin V, Crkvenjakov R, Byus C. Ribonucleic acid isolated by cesium chloride centrifugation. Biochemistry 1973; 13:2633-7.
48. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239:487-91.
49. Garni-Wagner BA, Lee ZH, Kim YJ, Wilde C, Kang CY, Kwon BS. 4-1BB is expressed on CD45RAhiROhi transitional T cell in humans. Cell Immunol 1996; 169:91-8.
50. Vinay DS, Kwon BS. Role of 4-1BB in immune response. Sem Immunol 1998; 10:481-9.
51. - T cells. J Immunol 1997; 158:3081-9.
52. Seo A, Ishikawa F, Nakano H, Nakazaki H, Kobayashi K, Kakiuchi T. Enhancement of B7-1 (CD80) expression on B-lymphoma cells by irradiation. Immunology 1999; 96:642-8.
53. Xiang J. Expression of co-stimulatory 4-1BB ligand induces significant tumor regression and protective immunity. Cancer Biother Radiopharm 1999; 14:353-61.
54. Mogi S, Sakurai J, Kohsaka T, Enomoto S, Yagita H, Okumura K, Azuma M. Tumour rejection by gene transfer of 4-1BB ligand into a CD80 (+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells. Immunology 2000; 101:541-7.
55. Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors. Cell Immunol 2001; 210:56-65.